Project Grant 2304222
Award Date
8/15/23
Completion Date
7/31/24
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Brainstorm Therapeutics, Inc. aims to develop and validate a novel Parkinson's disease drug discovery platform using patient-derived midbrain organoids. The platform will guide therapeutic candidate identification, patient selection, and trial endpoint refinement to accelerate the development of effective disease-modifying Parkinson's treatments. Key innovations...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,864 to Core Biotherapeutics Inc. aims to develop a platform for disruptive drug candidates that can reprogram molecular networks to produce therapeutic effects beyond single-target approaches. The key objectives are to: 1) demonstrate that oligonucleotide drug efficacy is a function of transcription factor (TF) network reprogramming using a breast cancer cell line, 2) build a...
The National Science Foundation (NSF) awarded a $274,966 Project Grant to Remedium Bio Inc., a for-profit organization, under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant supports the development of an adjustable gene therapy platform technology that will enable the use of genetic therapeutics beyond rare diseases, tackling large unmet clinical needs such as diabetes, osteoarthritis, and autoimmune diseases. The project aims to develop a dose-adjustable...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Vivosphere LLC aims to develop a more physiologically relevant, consistent, and versatile high-throughput screening (HTS) model to improve the translation rate between preclinical and clinical cancer drug testing. The project will: 1) test additional cancer cell types to demonstrate the platform's broad applicability, 2) explore cryopreservation to reduce response...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Macula Vision Systems Inc., a for-profit organization, supports the development of a novel microscopy platform to automate the interpretation of microbiology lab tests performed in hospitals. The project aims to address the shortage of trained lab technicians by engineering a specialized light source, customized camera, and AI-enabled algorithms to analyze...
This $305,000 Small Business Innovation Research (SBIR) Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a new class of gene therapies delivered more safely, cost-effectively, and at scale for serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes,...
This NSF Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Zebramd Inc. aims to develop an electronic health record (EHR) integrated artificial intelligence system capable of predicting rare diseases in undiagnosed patients and providing evidence-based treatment recommendations for already diagnosed rare disease patients. The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to potentially improve the diagnosis and...
The National Science Foundation (NSF) awarded a $365,887 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to The Research Foundation For The State University Of New York (RF SUNY) for the project "PFI-RP: PRECISION DIAGNOSTICS FOR PERSONALIZED CANCER CARE: DEVELOPMENT OF NEW DRUGS AND SELECTION OF TREATMENT". This project aims to develop an innovative artificial intelligence (AI) technology to select optimal treatment options tailored to...
This $250,000 National Science Foundation Technology, Innovation, and Partnerships Project Grant supports the development of artificial substrates for growing human stem cells suitable for clinical applications at Oakland University from March 2023 to February 2025. The goal is to accelerate the potential benefits of using human pluripotent stem cells and their derivatives for treating and curing diseases by producing a synthetic substrate that supports growth of human pluripotent stem cells...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...